CoChat

The NINDS Parkinson's disease biomarkers program

Open access
Rosenthal, Liana S., Drake, Daniel, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen‐Plotkin, Alice, Dawson, Ted M., Dewey, Richard B., German, Dwight C., Huang, Xuemei, Landin, Barry, McAuliffe, Matthew, Petyuk, Vladislav A., Scherzer, Clemens R., Hillaire‐Clarke, Coryse St., Sieber, Beth‐Anne, Sutherland, Margaret, Tarn, Chi, West, Andrew, Vaillancourt, David, Zhang, Jing, Gwinn, Katrina, on behalf of the PDBP consortium · 2016 · Movement Disorders
Cited by 111

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory‐based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross‐project comparisons and assessment of batch effects. A web‐based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety‐eight total biosamples are available from baseline, 6‐, 12‐, and 18‐month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research. © 2015 International Parkinson and Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.26438

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Rosenthal, L. S., Drake, D., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen‐Plotkin, A., Dawson, T. M., Dewey, R. B., German, D. C., Huang, X., Landin, B., McAuliffe, M., Petyuk, V. A., Scherzer, C. R., Hillaire‐Clarke, C. S., Sieber, B., Sutherland, M., Tarn, C., West, A., Vaillancourt, D., Zhang, J., Gwinn, K., & on behalf of the PDBP consortium
Venue
Movement Disorders
Publisher
Wiley
Published
2015-10-07
Volume
31
Issue
6
Pages
915-923
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W1922627767
Cited by
111
References
2
FWCI
6.07
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.